Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Increase in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 103,900 shares, an increase of 76.1% from the November 30th total of 59,000 shares. Based on an average trading volume of 2,220,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 3.6% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Chardan Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Senti Biosciences in a research note on Monday, December 2nd.

Senti Biosciences Stock Performance

SNTI traded down $0.22 during midday trading on Friday, hitting $3.92. The stock had a trading volume of 73,351 shares, compared to its average volume of 774,802. Senti Biosciences has a 1 year low of $1.52 and a 1 year high of $16.94. The business has a fifty day moving average of $3.45 and a 200 day moving average of $2.89. The company has a market cap of $17.99 million, a P/E ratio of -0.25 and a beta of 2.69.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.